Brenda Moura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/554612/publications.pdf Version: 2024-02-01



| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | statement on behalf of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> ssociation (<scp>HFA</scp>), the <scp>E</scp> uropean <scp>A</scp> ssociation of <scp>C</scp> ardiovascular <scp>I</scp> maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp> ouncil of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology (<scp>ESC</scp>). European | 2.9 | 234 |
| 2 | Journal of Heart Failure, 2020, 22, 1504-1524. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576. | 2.9 | 224 |
| 3 | Selfâ€care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174. | 2.9 | 181 |
| 4 | The <scp>Heart Failure Association Atlas</scp> : <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. European Journal of Heart Failure, 2021, 23, 906-914. | 2.9 | 130 |
| 5 | Sodium–glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503. | 2.9 | 100 |
| 6 | Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959. | 2.9 | 75 |
| 7 | <scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium–glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986. | 2.9 | 66 |
| 8 | Pericardial Involvement in Human Immunodeficiency Virus Infection. Chest, 1999, 115, 418-422. | 0.4 | 51 |
| 9 | Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. International Journal of Cardiology, 1998, 63, 37-45. | 0.8 | 44 |
| 10 | Iron Deficiency Status Irrespective of Anemia: A Predictor of Unfavorable Outcome in Chronic Heart Failure Patients. Cardiology, 2014, 128, 320-326. | 0.6 | 40 |
| 11 | Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437. | 2.9 | 36 |
| 12 | <scp>COVID</scp> â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818. | 2.9 | 32 |
| 13 | Cardiac remodelling–ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943. | 2.9 | 29 |
| 14 | From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure. Heart Failure Reviews, 2020, 25, 217-230. | 1.7 | 27 |
| 15 | The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. European Heart Journal, 2021, 42, 657-670. | 1.0 | 25 |
| 16 | The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645. | 2.9 | 23 |
| 17 | Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596. | 2.9 | 23 |
| 18 | Cardiac remodelling–ÂPart 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958. | 2.9 | 22 |

Brenda Moura

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy. Revista Portuguesa De Cardiologia, 2016, 35, 253-260. | 0.2 | 20 |
| 20 | Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients. International Journal of Cardiology, 1997, 59, 285-289. | 0.8 | 16 |
| 21 | Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction. International Journal of Cardiovascular Imaging, 2017, 33, 605-613. | 0.7 | 16 |
| 22 | Portuguese study of familial dilated cardiomyopathy: the FATIMA study. Revista Portuguesa De Cardiologia, 2008, 27, 1029-42. | 0.2 | 12 |
| 23 | Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 253-260. | 0.2 | 11 |
| 24 | The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. Revista Portuguesa De Cardiologia, 2017, 36, 709-716. | 0.2 | 11 |
| 25 | Zidovudine Therapy and Left Ventricular Function and Mass in Human Immunodeficiency Virus-Infected Patients. Cardiology, 1997, 88, 26-28. | 0.6 | 10 |
| 26 | Genetic variants identified by target next-generation sequencing in heart transplant patients with dilated cardiomyopathy. Revista Portuguesa De Cardiologia, 2019, 38, 441-447. | 0.2 | 10 |
| 27 | Predictors of myocardial dysfunction in human immunodeficiency virus-infected patients. Journal of Cardiac Failure, 1998, 4, 19-26. | 0.7 | 6 |
| 28 | The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 709-716. | 0.2 | 5 |
| 29 | Genetic Variants Are Not Rare in ICD Candidates with Dilated Cardiomyopathy: Time for Next-Generation Sequencing?. Cardiology Research and Practice, 2019, 2019, 1-9. | 0.5 | 3 |
| 30 | The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. Cardiologia Croatica, 2021, 16, 140-156. | 0.0 | 0 |